HALIFAX, Oct. 7 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer of rapid diagnostics and rapid flow-through
technology, announced today that it has made an initial shipment of its
Multiplo HBV/HIV/HCV Rapid Tests (Multiplo HBV/HIV/HCV) to its regional
distribution partner in Romania, S.C. Roned International S.R.L. They have
received approval to sell Multiplo HBV/HIV/HCV in Moldova and Ukraine and will
immediately begin selling to public health programs and participating in NGO
"We are excited to build upon the success we have had with MedMira rapid
tests in Romania. The Multiplo test is a perfect product for the market here
in Romania, Moldova, and Ukraine, where HIV/Hepatitis co-infections are on the
rise," said Dumitru Vescu, Executive Director of S.C. Roned International
S.R.L. and President of the Romania-Moldova Chamber of Commerce and Industry.
"We have had a great response with the initial introduction of this product
and will now move to a wider distribution of these tests to our customers.
MedMira has been an excellent partner and we look forward to adding new
MedMira rapid tests to our line of products in the future."
Multiplo HBV/HIV/HCV is one of MedMira's multiple rapid diagnostic tests
which simultaneously detect antibodies to HIV and the hepatitis B and C
viruses in a single drop of blood. Multiplo stands alone as the only
commercially available rapid test for HIV and Hepatitis co-infection. Multiplo
was launched earlier this year in the United Nations Office on Drugs and Crime
(UNODC) Behavioural Surveillance Surveys (BSS) Among Injecting Drug Users and
Sex Workers in Romania.
"We are seeing exciting growth opportunities in Eastern Europe for
MedMira's products as governments and healthcare systems continue to integrate
rapid tests for HIV and Hepatitis in to prevention and control programs," said
Hermes Chan, president and CEO, MedMira Inc. "Dumitru and his team know this
market well and they are continually seeking new opportunities to expand the
distribution and sales of our rapid tests in South Eastern Europe."
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, email@example.com; Andrea Young, Corporate
Communications, (902) 450-1588, firstname.lastname@example.org